☰

Empresas y finanzas

Mylan says Teva's stake buy violates U.S. anti-trust rules


    (Reuters) - Mylan NV said Teva Pharmaceutical Industries Ltd , which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake.

    Teva disclosed a 1.35 percent stake in MYLAN (MYL.NQ)(MYL.NQ)last week.

    "We consider Teva's stakebuilding as a further indication of its intention to meddle with our business, strategy and mission while remaining unclear as to its actual intentions," Mylan said in a letter addressed to Teva's chief executive, Erez Vigodman.(http://1.usa.gov/1Q0SxgC)

    Mylan did not clarify which anti-trust rule Teva violated.

    The two companies were not immediately available for comment.

    Mylan said on Monday there was still no clarity whether Teva would make a formal offer, almost six weeks since Teva's offer for about $40 billion.

    (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Maju Samuel)